project id: TCGA-UCEC; case submitter id: TCGA-KP-A3W1; source center: 23; state: released; a260 a280 ratio: 1.87; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.0; rna integrity number: 7.1; age at index: 76; days to birth: -27902; ethnicity: not reported; gender: female; race: not reported; vital status: Alive; year of birth: 1935; age at diagnosis: 27902; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 288.0; figo stage: Stage IA; icd 10 code: C54.1; last known disease status: not reported; morphology: 8441/3; primary diagnosis: Serous cystadenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Endometrium; synchronous malignancy: No; tissue or organ of origin: Endometrium; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: yes; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 198; initial weight: 710.0; sample id: 1ad2a1ca-75e0-4f9f-808d-768cb14bdff3; sample submitter id: TCGA-KP-A3W1-01A; portion id: fa733adc-358d-4c12-b78a-c283504c9e4e; portion submitter id: TCGA-KP-A3W1-01A-11; slide id: 9f0c6ab0-95ac-482b-8121-af2c88ec6f17; slide submitter id: TCGA-KP-A3W1-01A-01-TS1; percent lymphocyte infiltration: 60.0; percent monocyte infiltration: 20.0; percent necrosis: 5.0; percent neutrophil infiltration: 10.0; percent normal cells: 0.0; percent stromal cells: 5.0; percent tumor cells: 90.0; percent tumor nuclei: 90.0; section location: TOP;